📢 Stocks Trending NOW: #SMCI #GE #PL #SPOT #FDX #DELL #CODX #AZTR #ARM #TSEM

Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million Initial funding of approximately $10. 5 MM in convertible preferred stock and up to an additional $20. 9 MM upon cash exercise of warrants. The financing is for gross proceeds of up to approximately $31.4 million to the Company, including initial gross proceeds of approximately $10.5 million and up to an additional $20.9 million in gross proceeds upon the...

#AZTR Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

www.stocktitan.net/news/AZTR/azitra-announc...

Full Alliance Group (OTC: FAGI) Multi-Division Ecosystem Future Giant Spotlight to Watch Among AZTR, ELPW, JEM, ADMQ Now Getting your Trinity Audio player ready... Full Alliance Group, Inc. (OTC: FAGI) is emerging as a diversified microcap company executing a multi-division strategy that combines operating businesses with next-generation digital infrastructure initiatives. As investor interest grows around companies bridging traditional commerce, blockchain infrastructure, and tokenized finance, Full Alliance Group is developing an ecosystem designed to connect […]

#FAGI Full Alliance Group (OTC: FAGI) Multi-Division Ecosystem Future Giant Spotlight
thestreetreports.com/full-allianc...
#AZTR, #ELPW, #JEM, #ADMQ

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders BRANFORD, Conn., March 5, 2026/ PRNewswire/-- Azitra, Inc., a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until...

#AZTR Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates Azitra (NYSE American: AZTR) reported full-year 2025 results and clinical progress. Key clinical advances include dosing the first patient in the Phase 1/2 ATR-04 trial (EGFRi-associated rash), Fast Track designation for ATR-04, promising Phase 1b safety data for ATR-12 in Netherton syndrome, and positive preclinical ATR-01 data.Financials: R&D $4.8M, G&A $6.2M, net loss $11.0M, and cash & equivalents $2.1M; completed $8.5M financing activity in 2025.

#AZTR Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American BRANFORD, Conn., Dec. 17, 2025/ PRNewswire/-- Azitra, Inc., a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC approving Azitra's plan to come into compliance with the Exchange's continued listing standards under Section 1003...

#AZTR Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

www.stocktitan.net/news/AZTR/azitra-receive...

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules Azitra (NYSE American: AZTR) entered a private placement with a single institutional investor to sell 4,687,500 shares of common stock (or pre-funded warrants in-lieu) together with warrants to purchase up to 4,687,500 shares.The combined effective offering price per share plus warrant is $0.32, producing estimated gross proceeds of approximately $1.5 million before placement agent fees and expenses. The warrants have an exercise price of $0.32, will be exercisable upon shareholder approval, and expire five years after that approval. The Offering is expected to close on or about November 25, 2025. Maxim Group is sole placement agent. The company has agreed to file a resale registration statement with the SEC.

#AZTR Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

www.stocktitan.net/news/AZTR/azitra-inc-ann...

#AZTR: ATR-01 Data Presented buff.ly/BrQW8uX

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates Azitra (NYSE American: AZTR) reported Q3 2025 results and business updates on Nov 12, 2025. Key operational highlights: dosed first patient in the Phase 1/2 ATR-04 trial for EGFRi-associated rash (Aug 2025) and presented positive preclinical data for ATR-01 at BIO-Europe. The company raised $2.8M under an equity line with Alumni Capital LP. Financials: R&D expense was $1.2M (Q3 2025) vs $1.0M (Q3 2024); G&A was $1.6M vs $1.9M; net loss was $2.8M vs $1.0M; cash and cash equivalents were $1.4M as of Sept 30, 2025.The company said it continues to advance ATR-12, ATR-04, and ATR-01 programs derived from its topical live biotherapeutic platform.

#AZTR Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Azitra, Inc. Addresses False Report Regarding Sale of Securities Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.

#AZTR Azitra, Inc. Addresses False Report Regarding Sale of Securities

www.stocktitan.net/news/AZTR/azitra-inc-add...

Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris. BRANFORD, Conn., Oct. 20, 2025/ PRNewswire/-- Azitra, Inc., a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis...

#AZTR Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

www.stocktitan.net/news/AZTR/azitra-inc-ann...

🚀 Exciting times for #AZTR! Trading at $1.07, it's showing bullish momentum with a 10-day SMA of $0.93 and a 20-day EMA of $1.03. RSI at 61.5 hints at an uptrend continuation. Consider entering at $1.05, targeting $1.15 & $1.20. Stay sharp, watch the market! 📈 #FeetrAI

🚀 Exciting times for #AZTR! With a breakthrough in dermatology research and bullish technicals like RSI at 61.5, this stock is poised for growth. Current price: $1.07, targeting $1.15 & $1.20. Analysts are buzzing—could this be your next big win? 📈 #FeetrAI #StocksToWatch

Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash Azitra (NYSE American: AZTR) has initiated dosing in a Phase 1/2 clinical trial for ATR04-484, a topical live biotherapeutic treatment targeting EGFR inhibitor (EGFRi)-associated rash. The condition affects approximately 150,000 people annually in the U.S. and has received FDA Fast Track designation.The multicenter, randomized, double-blind, vehicle-controlled study (NCT06830863) will evaluate ATR04-484's safety and tolerability in adult patients. The treatment addresses a critical medical need, as EGFRi-associated rash affects 50-80% of cancer patients receiving EGFR inhibitor treatments, often leading to cancer treatment interruption or discontinuation.ATR04-484 is derived from a specially engineered Staphylococcus epidermidis strain, designed to reduce IL-36γ and S. aureus levels, which are elevated in affected patients.

#AZTR Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash

www.stocktitan.net/news/AZTR/azitra-inc-ann...

#AZTR: Second Quarter Update buff.ly/YwJoFua

Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus - Azitra (AMEX:AZTR), Aptorum Group (NASDAQ:APM) U.S. stock futures rose on Friday following Thursday's declines. Futures of major benchmark indices were higher.

Stock Market Today: Dow, S&P 500 Futures Rise As Wall Street Awaits Powell's Jackson Hole Keynote—Azitra, Zoom Among Top Movers (UPDATED) U.S. stock futures rose on Friday following Thurs...

#APM #AZTR #BJ #BKE #COTY #Earnings #EEIQ #Equities #GFI #HSON #INTU

Origin | Interest | Match

Catching up with Azitra (#AZTR) co-founder Travis Whitfill on the company’s lead program ATR-12, pipeline strategy & the role of synthetic biology in dermatology youtu.be/VEGv-eC3OOU

#Biotech #Investing #AZTR

Azitra's Breakthrough: Promising Safety Results in Netherton Syndrome Treatment Trial as Pipeline Advances Positive safety data emerges from Azitra's Phase 1b Netherton syndrome trial. Pipeline expands with new cancer-related skin condition treatment. See milestone timeline.

#AZTR Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Azitra Reduces Share Count by 85%: Key Details of 1-for-6.66 Reverse Split Revealed New 1:6.66 ratio reduces outstanding shares from 23.4M to 3.5M. Learn how this affects your holdings, fractional shares treatment, and trading timeline. Get details.

#AZTR Azitra, Inc. Announces Reverse Stock Split

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome Azitra (NYSE: AZTR) reported positive initial safety data from its Phase 1b trial of ATR12-351, a live biotherapeutic candidate for Netherton syndrome, a rare genetic skin disorder affecting 1 in 200,000 people. The trial, now 50% enrolled with six patients dosed, shows ATR12-351 has been generally safe and well-tolerated when applied topically. The treatment aims to deliver engineered S. epidermidis bacteria to replace deficient LEKTI protein in the skin. While some mild to moderate application site reactions were observed, these were transient and occurred bilaterally, suggesting they were not drug-related. No severe or serious adverse events have been reported. The trial remains blinded, and efficacy data is not yet available. ATR12-351 represents a potential breakthrough for Netherton syndrome, which currently has no cure and limited treatment options.

#AZTR Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

www.stocktitan.net/news/AZTR/azitra-reports...

Azitra Reveals Latest Clinical Progress: Two Novel Dermatology Treatments Take Center Stage at BIO 2025 Get exclusive updates on Azitra's Phase 1b Netherton syndrome trial and EGFRi dermal toxicity treatment program. Key pipeline developments revealed at BIO 2025.

#AZTR Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

www.stocktitan.net/news/AZTR/azitra-inc-ann...

Revolutionary Skin Microbiome Treatment Could Help Cancer Patients Stay on Life-Saving Therapy Novel biologic ATR04-484 targets severe skin rash that forces cancer patients off treatment. FDA Fast Track designated therapy debuts Phase 1/2 data. Learn more.

#AZTR Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash

www.stocktitan.net/news/AZTR/azitra-inc-ann...

#AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025 buff.ly/pZR8k1b

Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates Azitra (NYSE: AZTR) reported its Q1 2025 financial results and provided business updates. The company secured up to $20 million in funding through a partnership with Alumni Capital LP and raised an additional $2.2 million through public offerings. Key developments include acceptance of a poster presentation at ASCO 2025 for their ATR-04 program targeting EGFR inhibitor-associated rash.The company expects initial safety data from their ATR-12 Phase 1b trial for Netherton syndrome in 1H 2025, with topline results by year-end. They also plan to begin dosing patients in a Phase 1/2 trial for ATR-04 by mid-2025. Financial results show R&D expenses of $1.3 million, G&A expenses of $1.9 million, and a net loss of $3.1 million for Q1 2025. Cash position stands at $3.2 million as of March 31, 2025.

#AZTR Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

www.stocktitan.net/news/AZTR/azitra-inc-ann...

$20M Strategic Investment Accelerates Azitra's Breakthrough Treatments for 150,000 Rare Disease Patients New funding deal fuels development of innovative treatments for Netherton Syndrome and EGFRi rash. Flexible 20-month agreement minimizes dilution. See development timeline.

#AZTR Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline

www.stocktitan.net/news/AZTR/azitra-announc...

#AZTR Azitra's COO Travis Whitfill Gives Outlook on ATR-12